GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (FRA:7CA) » Definitions » Return-on-Tangible-Equity

Camurus AB (FRA:7CA) Return-on-Tangible-Equity : 15.16% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Camurus AB Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Camurus AB's annualized net income for the quarter that ended in Mar. 2024 was €27.5 Mil. Camurus AB's average shareholder tangible equity for the quarter that ended in Mar. 2024 was €181.6 Mil. Therefore, Camurus AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was 15.16%.

The historical rank and industry rank for Camurus AB's Return-on-Tangible-Equity or its related term are showing as below:

FRA:7CA' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -77.62   Med: -18.86   Max: 74.25
Current: 28.32

During the past 13 years, Camurus AB's highest Return-on-Tangible-Equity was 74.25%. The lowest was -77.62%. And the median was -18.86%.

FRA:7CA's Return-on-Tangible-Equity is ranked better than
94.58% of 1311 companies
in the Biotechnology industry
Industry Median: -47.81 vs FRA:7CA: 28.32

Camurus AB Return-on-Tangible-Equity Historical Data

The historical data trend for Camurus AB's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Return-on-Tangible-Equity Chart

Camurus AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.39 -24.11 -11.07 6.03 35.10

Camurus AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.21 98.94 24.32 -4.26 15.16

Competitive Comparison of Camurus AB's Return-on-Tangible-Equity

For the Biotechnology subindustry, Camurus AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Camurus AB's Return-on-Tangible-Equity falls into.



Camurus AB Return-on-Tangible-Equity Calculation

Camurus AB's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=38.57/( (88.331+131.436 )/ 2 )
=38.57/109.8835
=35.10 %

Camurus AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=27.52/( (131.436+231.734)/ 2 )
=27.52/181.585
=15.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Camurus AB  (FRA:7CA) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Camurus AB Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Camurus AB's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Camurus AB (FRA:7CA) Business Description

Industry
Traded in Other Exchanges
Address
Ideon Science Park, Lund, SWE, SE-223 70
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The company's product pipeline includes CAM2038, CAM2029, CAM2032, and others. The company's geographical revenue includes Europe (of which Sweden), the United States of America, Australia, and Other geographical areas.

Camurus AB (FRA:7CA) Headlines

No Headlines